Europe, UK (Commonwealth Union) – The UK government has stated that a public-private partnership has been launched to stimulate economic growth and create a future-ready NHS.
It was indicated that via this initiative, NHS patients will gain fast-tracking to new treatments, and the UK will establish itself as a leader in advanced health research. The UK government is rolling out a joint public-private investment programme valued at up to £400 million.
The Voluntary Scheme for Branded Medicine Pricing, Access, and Growth (VPAG) Investment Programme, which recently launched, is set to drive substantial investment into the UK’s health and life sciences sector over the next five years. This effort aims to boost economic growth and enhance the global standing of the UK’s life sciences industry.
The government pointed out that the initiative represents the world’s first major collaboration of its kind, designed to bolster the NHS by supporting pioneering research. It will establish 18 new clinical trial hubs to accelerate the development of new medicines, ensuring they reach patients faster. By optimizing processes, the programme will facilitate the swift transition of new treatments from research labs to hospital wards, offering patients quicker access to state-of-the-art therapies.
Health and Social Care Secretary Wes Streeting stated that this private investment reflects strong confidence in the UK and will accelerate the delivery of the next wave of treatments to NHS patients.
He further pointed out that it will boost the UK’s global standing and establish the country as a central hub for health research, helping to create a future-ready NHS.
“By cutting waiting lists and fixing our NHS, we can make it an engine for growth and build the healthy society needed for a healthy economy,” said the Health Secretary.
The Voluntary Pricing and Access Agreement (VPAG) is a collaborative initiative between the Department of Health and Social Care (DHSC), NHS England, and the Association of the British Pharmaceutical Industry (ABPI). It aims to enhance patient outcomes, manage the NHS medicines budget, and support the life sciences sector. As part of the scheme, additional investments from pharmaceutical companies will help implement the associated UK investment programme.
Health problems across the world have highlighted the need for new medicines and quicker access to medicines on trial.
